GLASGOW-based chemistry technology pioneer DeepMatter has won an endorsement from an Indian pharmaceuticals firm.

DeepMatter will supply its DigitalGlassware technology to Aurigene Pharmaceutical Services for use on a paid-for trial basis.

Aurigene provides contract research, development and manufacturing services for other companies.

DeepMatter said Aurigene would use DigitalGlassware to help screen, develop and scale up chemistry procedures and to accelerate custom drug discovery and development projects.

DigitalGlassware can be used to store information online about compounds produced in experiments and the conditions under which tests were completed.

READ MORE: Glasgow recruitment technology firm to create jobs itself

Aurigene chief executive Ravi Venkataraman said: ”Digital transformation leveraging Artificial Intelligence (AI)/Machine Learning (ML) tools is a key focus area and our collaboration with DeepMatter is one step towards faster patient centric innovation.”

Aurigine is a subsidiary of India’s Dr Reddy’s laboratories. DeepMatter agreed a collaboration deal with the group in September.

DeepMatter chief executive Mark Warne noted at the time that the company was focused on creating value for the world's largest contract research organisations with the DigitalGlassware platform.

Aim market- listed DeepMatter was spun out of the University of Glasgow by Lee Cronin in 2014. It employs 17 people in Glasgow.

READ MORE: Digital chemistry firm impresses big guns

Shares in the firm closed up four per cent, 0.05p, at 1.28p.